Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 18;12(14):4744.
doi: 10.3390/jcm12144744.

The Role of Donor Gamma-Glutamyl Transferase as a Risk Factor for Early Graft Function after Liver Transplantation

Quirino Lai  1 , Fabio Melandro  1 , Tommaso M Manzia  2 , Gabriele Spoletini  3 , Anna Crovetto  4 , Gaetano Gallo  1 , Redan Hassan  1 , Gianluca Mennini  1 , Roberta Angelico  2 , Alfonso W Avolio  3 , Frederik Berrevoet  4 , Luís Abreu de Carvalho  4 , Salvatore Agnes  3 , Giuseppe Tisone  2 , Massimo Rossi  1
Affiliations

The Role of Donor Gamma-Glutamyl Transferase as a Risk Factor for Early Graft Function after Liver Transplantation

Quirino Lai et al. J Clin Med. .

Abstract

Background: Growing interest has been recently reported in the potential detrimental role of donor gamma-glutamyl transferase (GGT) peak at the time of organ procurement regarding the risk of poor outcomes after liver transplantation (LT). However, the literature on this topic is scarce and controversial data exist on the mechanisms justifying such a correlation. This study aims to demonstrate the adverse effect of donor GGT in a large European LT cohort regarding 90-day post-transplant graft loss.

Methods: This is a retrospective international study investigating 1335 adult patients receiving a first LT from January 2004 to September 2018 in four collaborative European centers.

Results: Two different multivariable logistic regression models were constructed to evaluate the risk factors for 90-day post-transplant graft loss, introducing donor GGT as a continuous or dichotomous variable. In both models, donor GGT showed an independent role as a predictor of graft loss. In detail, the log-transformed continuous donor GGT value showed an odds ratio of 1.46 (95% CI = 1.03-2.07; p = 0.03). When the donor GGT peak value was dichotomized using a cut-off of 160 IU/L, the odds ratio was 1.90 (95% CI = 1.20-3.02; p = 0.006). When the graft-loss rates were investigated, significantly higher rates were reported in LT cases with donor GGT ≥160 IU/L. In detail, 90-day graft-loss rates were 23.2% vs. 13.9% in patients with high vs. low donor GGT, respectively (log-rank p = 0.004). Donor GGT was also added to scores conventionally used to predict outcomes (i.e., MELD, D-MELD, DRI, and BAR scores). In all cases, when the score was combined with the donor GGT, an improvement in the model accuracy was observed.

Conclusions: Donor GGT could represent a valuable marker for evaluating graft quality at transplantation. Donor GGT should be implemented in scores aimed at predicting post-transplant clinical outcomes. The exact mechanisms correlating GGT and poor LT outcomes should be better clarified and need prospective studies focused on this topic.

Keywords: donor risk index; expanded-criteria donor; graft loss; liver transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare in relation to the present study.

Figures

Figure 1
Figure 1
Graft-loss rates reported in patients transplanted receiving grafts from donors with high (≥160 IU/L) vs. low (<160 IU/L) GGT values.
See this image and copyright information in PMC

References

    1. Adam R., Karam V., Cailliez V., Grady J.G.O., Mirza D., Cherqui D., Klempnauer J., Salizzoni M., Pratschke J., Jamieson N., et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR)-50-year evolution of liver transplantation. Transpl. Int. 2018;31:1293–1317. doi: 10.1111/tri.13358. - DOI - PubMed
    1. Lerut J., Foguenne M., Lai Q. Hepatocellular cancer selection systems and liver transplantation: From the tower of babel to an ideal comprehensive score. Updat. Surg. 2021;73:1599–1614. doi: 10.1007/s13304-021-01078-4. - DOI - PMC - PubMed
    1. Quaresima S., Melandro F., Giovanardi F., Shah K., De Peppo V., Mennini G., Ghinolfi D., Limkemann A., Pawlik T.M., Lai Q. New Insights in the Setting of Transplant Oncology. Medicina. 2023;59:568. doi: 10.3390/medicina59030568. - DOI - PMC - PubMed
    1. Ravaioli M., Lai Q., Sessa M., Ghinolfi D., Fallani G., Patrono D., Di Sandro S., Avolio A., Odaldi F., Bronzoni J., et al. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy. J. Hepatol. 2022;76:619–627. doi: 10.1016/j.jhep.2021.10.024. - DOI - PubMed
    1. Lai Q., Sapisochin G., Gorgen A., Vitale A., Halazun K.J., Iesari S., Schaefer B., Bhangui P., Mennini G., Wong T.C., et al. Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. JAMA Surg. 2021;156:e213112. doi: 10.1001/jamasurg.2021.3112. - DOI - PMC - PubMed

LinkOut - more resources